Filtered By:
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 4921 results found since Jan 2013.
Analysis of hepatocellular carcinoma associated with hepatitis B virus
J Cell Mol Med. 2023 Jul 30. doi: 10.1111/jcmm.17867. Online ahead of print.ABSTRACTThe hepatitis B virus (HBV) is considered one of the main driving forces in the development of hepatocellular carcinoma (HCC). Human HBV is a partially double-stranded DNA (dsDNA) virus consisting of approximately 3.2 kbp. HBV predominantly infects hepatocytes via the receptor sodium taurocholate cotransporting polypeptide (NTCP) and coreceptor hepatic proteoglycan. The replication of HBV in hepatocytes leads to apoptosis while simultaneously leading to cirrhosis and cancer. Although the integration of dsDNA into the hepatocyte genome seems...
Source: J Cell Mol Med - July 30, 2023 Category: Molecular Biology Authors: Litao Zheng Source Type: research
Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021
ConclusionsHepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.PMID:37498531 | PMC:PMC10375835 | DOI:10.2807/1560-7917.ES.2023.28.30.2200837
Source: Euro Surveill - July 27, 2023 Category: Infectious Diseases Authors: Nino Khetsuriani Amiran Gamkrelidze Shaun Shadaker Maia Tsereteli Maia Alkhazashvili Nazibrola Chitadze Irina Tskhomelidze Lia Gvinjilia Francisco Averhoff Gavin Cloherty Qian An Giorgi Chakhunashvili Jan Drobeniuc Paata Imnadze Khatuna Zakhashvili Paige Source Type: research
Frequency of B-Cell Subpopulations in Low Responders in Comparison with High Responders to Hepatitis B Vaccine Among Health Care Workers
This study aimed to evaluate the frequency of different B-cell subpopulations and the expression of PD-1 on B-cell subsets in low responders (LR) and high responders (HR) to HB vaccine. According to our findings, the expression level of PD-1 was significantly higher on atypical MBC (atMBC) than that of naive B cell and classical MBC (cMBC) in LR and HR groups. Moreover, cMBCs had a significant higher PD-1 expression than naive B cells in LR group. No significant differences were found in the frequency of various B-cell subpopulations and the expression level of PD-1 on B-cell subsets between LR and HR groups. We observed a...
Source: Current Microbiology - July 24, 2023 Category: Microbiology Authors: Zahra Saleh Fereshteh Mehdipour Mohammad Reza Ataollahi Mohammad Ali-Hassanzadeh Dieter Kabelitz Kurosh Kalantar Source Type: research
HBV Infection Is an Intermediate-Risk Disease, Whereas Anaemia Is a Mild-to-Moderate Public Health Problem in Young Ghanaian Adults: A Four-Year Retrospective Analysis of Students' Medical Records
CONCLUSION: Intentional preventative public health campaigns regarding anaemia, HBV, and HCV infection should, respectively, target females and young adult males to increase chances of making real change in behavioural attitudes in these at-risk groups.PMID:37475793 | PMC:PMC10356218 | DOI:10.1155/2023/9318984
Source: Biomed Res - July 21, 2023 Category: Research Authors: Samuel Amoah Andrew Nicholas Yartey Praise Fosu Adjei Margaret Owusu-Akyaw Joseph Boachie David Larbi Simpong Patrick Adu Source Type: research
Past, present, and future of long-term treatment for hepatitis B virus
World J Gastroenterol. 2023 Jul 7;29(25):3964-3983. doi: 10.3748/wjg.v29.i25.3964.ABSTRACTThe estimated world prevalence of hepatitis B virus (HBV) infection is 316 million. HBV infection was identified in 1963 and nowadays is a major cause of cirrhosis and hepatocellular carcinoma (HCC) despite universal vaccination programs, and effective antiviral therapy. Long-term administration of nucleos(t)ide analogues (NA) has been the treatment of choice for chronic hepatitis B during the last decades. The NA has shown a good safety profile and high efficacy in controlling viral replication, improving histology, and decreasing th...
Source: World Journal of Gastroenterology - July 21, 2023 Category: Gastroenterology Authors: Teresa Broquetas Jos é A Carrión Source Type: research
